Furthermore, a study by Allenson et al. found that a higher percentage of patients with early stage pancreatic cancer exhibited detectable KRAS mutations in exoDNA than previously reported for cfDNA [47]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.